InsidersTradesSigma
LH
Lucira Health, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Lucira Health, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Lucira Health, Inc. has logged 32 reports. The latest transaction was reported on 13 March 2023 (Cession). Among the most active insiders: Kashmolah Ghazi. The full history is accessible without an account.
32
Insider Decl.
0
Thresholds
€132,813
3 ops.
Buy Volume
€289,693
22 ops.
Sell Volume
45Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 13 March 2023
Declarations32 total
30,102 shares@ US$1.1527.1% of flowCommon StockSEC:0001209191-23-018223:0
10,674 shares@ US$1.1495.5% of flowCommon StockSEC:0001209191-23-018225:0
8,405 shares@ US$1.0023.7% of flowCommon StockSEC:0001209191-23-018219:0
574,666 shares@ US$0.8277.0% of flowCommon StockSEC:0001209191-23-018261:0
5,028 shares@ US$0.271.1% of flowCommon StockSEC:0001209191-23-011047:0
4,263 shares@ US$0.161.9% of flowCommon StockSEC:0001209191-22-062409:0
3,461,764 sharesCommon StockSEC:0001667731-22-000447:0
3,429 shares@ US$0.333.3% of flowCommon StockSEC:0001209191-22-060495:0
7,537 shares@ US$0.422.7% of flowCommon StockSEC:0001209191-22-060487:0
8,011 shares@ US$0.382.6% of flowCommon StockSEC:0001209191-22-060480:0
1,583 shares@ US$0.364.5% of flowCommon StockSEC:0001209191-22-059999:0
9,666 shares@ US$0.423.2% of flowCommon StockSEC:0001209191-22-058925:0
4,790 shares@ US$0.351.4% of flowCommon StockSEC:0001209191-22-058008:0
17,052 shares@ US$1.3971.1% of flowCommon StockSEC:0001209191-22-051033:0
343 shares@ US$1.3820.6% of flowCommon StockSEC:0001209191-22-050767:0
20,000 shares@ US$1.826.3% of flowCommon StockSEC:0001209191-22-050460:0
Ideal exit: 12 Jun 2023 (T+270)
191 shares@ US$1.6948.0% of flowCommon StockSEC:0001209191-22-048920:0
8,580 shares@ US$1.7212.3% of flowCommon StockSEC:0001209191-22-047931:0
1,500 shares@ US$1.932.6% of flowCommon StockSEC:0001209191-22-047928:0
19,074 shares@ US$2.5242.2% of flowCommon StockSEC:0001209191-22-047309:0
19,074 shares@ US$2.8347.3% of flowCommon StockSEC:0001209191-22-046962:0
37,109 shares@ US$2.0057.4% of flowCommon StockSEC:0001209191-22-041962:0
1,289 shares@ US$4.689.1% of flowCommon StockSEC:0001209191-22-041963:0
1,321 shares@ US$1.4579.4% of flowCommon StockSEC:0001209191-22-041961:0
890 shares@ US$4.6892.0% of flowCommon StockSEC:0001209191-22-041964:0
25 of 32 declarations
About Lucira Health, Inc.
Lucira Health, Inc. was a U.S.-based medical technology company listed on the NASDAQ under ticker LHDX in the United States. Founded in 2013 under the name DiAssess Inc. and later renamed Lucira Health, the company was headquartered in Emeryville, California. Its business model centered on developing, manufacturing, and commercializing infectious-disease diagnostic tests designed for at-home use, with a value proposition built around speed, ease of use, and decentralized testing outside traditional laboratories. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1652724/000156459021017123/lhdx-10k_20201231.htm?utm_source=openai)) Lucira’s flagship product was its at-home COVID-19 test, which became one of the early rapid molecular self-tests authorized in the United States. That product gave the company meaningful visibility during the pandemic-driven surge in decentralized diagnostics. Over time, Lucira also presented itself as a broader respiratory-testing platform company, with SEC filings and investor communications referring to tests for influenza and other infectious diseases as part of its product and development strategy. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1652724/000119312522072139/d325713dex991.htm?utm_source=openai)) From a competitive standpoint, Lucira operated in a crowded in vitro diagnostics market dominated by much larger players with deeper commercial infrastructure, broader regulatory reach, and stronger balance sheets. Its differentiation came from combining molecular testing, home use, and fast turnaround times. However, that niche depended heavily on the post-pandemic trajectory of consumer demand and on Lucira’s ability to expand beyond a single COVID-led revenue driver. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1652724/000119312522072139/d325713dex991.htm?utm_source=openai)) Geographically, Lucira’s operational footprint was primarily U.S.-centric, anchored in California and accessed through the NASDAQ market in the United States. The company also referenced international expansion plans in its SEC materials and highlighted manufacturing and commercialization partnerships as part of its scale-up efforts. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1652724/000156459021017123/lhdx-10k_20201231.htm?utm_source=openai)) The most important recent development was the company’s financial deterioration and its Chapter 11 filing in February 2023. Following that restructuring process, Lucira’s assets were sold to Pfizer, fundamentally changing the investment case for the original standalone issuer. For investors, Lucira is best understood as a pandemic-era diagnostics growth story that later faced a sharp reset as COVID testing demand normalized and the company’s strategic options narrowed. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1652724/000119312523044968/d642141dex991.htm?utm_source=openai))
